Lipid metabolizing proteins may elevate susceptibility to dementia leading to differences in genetic makeup. PCR-restriction fragment length polymorphism technique is used for genotyping of LRPAP1 intron 5 insertion/deletion. The studies suggested that DD genotype and *D allele of LRPAP gene showed increased frequency for degenerative dementias on comparison with the control group and that LRPAP1-D allele remarkably increases the vulnerability to degenerative dementias. On genotyping of LRPAP1 polymorphism is observed because of 37 base pair insertion in intron 5. Also insertion allele being larger than deletion allele makes possible in detecting difference by gel electrophoresis. Suppression of receptor-binding domain of LRP LDLR is due to overexpression of LRPAP (the protein product of LRPAP gene). LRP gives protection across LDL by LRPAP and its downregulation may be subjected for an elevation of LDL and Ab-related neuronal toxicity as LRP supports in binding of ligand and internalization of LRP ligands like apo-E-enriched LDL cholesterol and Ab protein. Insertion/deletion is an intronic polymorphism of LRPAP gene, Influencing DD genotype and D allele for the synthesis of LRPAP protein can be lrp-mediated mechanism contributing to dementia. Concern for developing sensitivity for dementia is because of several shared common genetic platforms and DD genotype or D allele of LRPAP gene may be one such. So on 37-bp insertion/deletion that was studied as an intronic polymorphism, it could be having an unintended pursuit for lipid receptor protein by regulation of LRPAP expression, or it could be in linkage disequilibrium in addition to other biologically relevant polymorphism in the LRPAP1 or an adjacent gene in chromosome 4. Results being consistent with earlier study where the authors have endowed deletion allele frequency clearly high in late-onset Alzheimer’s disease patients on comparison with non-demented aged controls.
Mendelian forms of myopia has been identified in four consanguineous families and are the likely causal mutations implementing exome /autozygome investigated to recognize homozygous truncating variants in LRPAP1. Influencing TGF-β activity,chaperone of LRP1 is encoded by LRPAP1.Notably salient deficiency of LRP1 and upregulation of TGF-β in affected individuals cells, the known data being consistent on the importance of TGF-β in remodeling for the sclera of myopia and the increased frequency in individuals for myopia having Marfan syndrome which has characteristics of upregulated TGF-β signaling. Analysizing the absence of the normal protein was done with immunoblot for affected individuals having LRPAP1 mutations revealing the mutations in LRPAP1 probability of loss-of-function mutations. Encoding (Low Density Lipoprotein Receptor-Related Protein Associated protein 1) LRPAP is a largely expressed gene, and a 357 amino acid protein thought as a chaperone binding and protecting the lipoproteins receptor-related proteins LRP1 and LRP2. A model suggested by a study wherein LRPAP1 leading to deficiency of LRP1 which was responsible to pertubation of TGF-β regulation and might cause abnormal ECM remodeling in the eye development. On observation for increasing axial length was one of the salient features of Marfan syndrome also resulting in TGF-β supported the model. Therefore individuals having myopia responding to therapeutic strategy initiated before ECM remodeling could be considered as an approach for individuals with LRPAP1 related myopia.
^Korenberg JR, Argraves KM, Chen XN, Tran H, Strickland DK, Argraves WS (Jul 1994). "Chromosomal localization of human genes for the LDL receptor family member glycoprotein 330 (LRP2) and its associated protein RAP (LRPAP1)". Genomics. 22 (1): 88–93. doi:10.1006/geno.1994.1348. PMID7959795.
^Lou X, McQuistan T, Orlando RA, Farquhar MG (Apr 2002). "GAIP, GIPC and Galphai3 are concentrated in endocytic compartments of proximal tubule cells: putative role in regulating megalin's function". Journal of the American Society of Nephrology. 13 (4): 918–27. PMID11912251.
^Willnow TE, Sheng Z, Ishibashi S, Herz J (1994). "Inhibition of hepatic chylomicron remnant uptake by gene transfer of a receptor antagonist". Science (New York, N.Y.). 264 (5164): 1471–4. PMID7515194.
^ abSánchez L, Alvarez V, González P, González I, Alvarez R, Coto E (2001). "Variation in the LRP-associated protein gene (LRPAP1) is associated with late-onset Alzheimer disease". American Journal of Medical Genetics. 105 (1): 76–8. PMID11425005.
^Loeys BL, Dietz HC, Braverman AC, Callewaert BL, De Backer J, Devereux RB, Hilhorst-Hofstee Y, Jondeau G, Faivre L, Milewicz DM, Pyeritz RE, Sponseller PD, Wordsworth P, De Paepe AM (2010). "The revised Ghent nosology for the Marfan syndrome". Journal of Medical Genetics. 47 (7): 476–85. doi:10.1136/jmg.2009.072785. PMID20591885.
Carter CJ (2007). "Convergence of genes implicated in Alzheimer's disease on the cerebral cholesterol shuttle: APP, cholesterol, lipoproteins, and atherosclerosis". Neurochemistry International. 50 (1): 12–38. doi:10.1016/j.neuint.2006.07.007. PMID16973241.
Williams SE, Ashcom JD, Argraves WS, Strickland DK (May 1992). "A novel mechanism for controlling the activity of alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein. Multiple regulatory sites for 39-kDa receptor-associated protein". The Journal of Biological Chemistry. 267 (13): 9035–40. PMID1374383.
Kounnas MZ, Argraves WS, Strickland DK (Oct 1992). "The 39-kDa receptor-associated protein interacts with two members of the low density lipoprotein receptor family, alpha 2-macroglobulin receptor and glycoprotein 330". The Journal of Biological Chemistry. 267 (29): 21162–6. PMID1400426.
Strickland DK, Ashcom JD, Williams S, Battey F, Behre E, McTigue K, Battey JF, Argraves WS (Jul 1991). "Primary structure of alpha 2-macroglobulin receptor-associated protein. Human homologue of a Heymann nephritis antigen". The Journal of Biological Chemistry. 266 (20): 13364–9. PMID1712782.
Herz J, Goldstein JL, Strickland DK, Ho YK, Brown MS (Nov 1991). "39-kDa protein modulates binding of ligands to low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor". The Journal of Biological Chemistry. 266 (31): 21232–8. PMID1718973.
Furukawa T, Ozawa M, Huang RP, Muramatsu T (Aug 1990). "A heparin binding protein whose expression increases during differentiation of embryonal carcinoma cells to parietal endoderm cells: cDNA cloning and sequence analysis". Journal of Biochemistry. 108 (2): 297–302. PMID2229028.
Zheng G, Bachinsky DR, Stamenkovic I, Strickland DK, Brown D, Andres G, McCluskey RT (Apr 1994). "Organ distribution in rats of two members of the low-density lipoprotein receptor gene family, gp330 and LRP/alpha 2MR, and the receptor-associated protein (RAP)". The Journal of Histochemistry and Cytochemistry. 42 (4): 531–42. doi:10.1177/42.4.7510321. PMID7510321.
Jou YS, Goold RD, Myers RM (Nov 1994). "Localization of the alpha 2-macroglobulin receptor-associated protein 1 gene (LRPAP1) and other gene fragments to human chromosome 4p16.3 by direct cDNA selection". Genomics. 24 (2): 410–3. doi:10.1006/geno.1994.1643. PMID7535288.
Argraves KM, Battey FD, MacCalman CD, McCrae KR, Gåfvels M, Kozarsky KF, Chappell DA, Strauss JF, Strickland DK (Nov 1995). "The very low density lipoprotein receptor mediates the cellular catabolism of lipoprotein lipase and urokinase-plasminogen activator inhibitor type I complexes". The Journal of Biological Chemistry. 270 (44): 26550–7. doi:10.1074/jbc.270.44.26550. PMID7592875.
Van Leuven F, Hilliker C, Serneels L, Umans L, Overbergh L, De Strooper B, Fryns JP, Van den Berghe H (Jan 1995). "Cloning, characterization, and chromosomal localization to 4p16 of the human gene (LRPAP1) coding for the alpha 2-macroglobulin receptor-associated protein and structural comparison with the murine gene coding for the 44-kDa heparin-binding protein". Genomics. 25 (2): 492–500. doi:10.1016/0888-7543(95)80050-V. PMID7789983.
Medh JD, Fry GL, Bowen SL, Pladet MW, Strickland DK, Chappell DA (Jan 1995). "The 39-kDa receptor-associated protein modulates lipoprotein catabolism by binding to LDL receptors". The Journal of Biological Chemistry. 270 (2): 536–40. doi:10.1074/jbc.270.2.536. PMID7822276.
Korenberg JR, Argraves KM, Chen XN, Tran H, Strickland DK, Argraves WS (Jul 1994). "Chromosomal localization of human genes for the LDL receptor family member glycoprotein 330 (LRP2) and its associated protein RAP (LRPAP1)". Genomics. 22 (1): 88–93. doi:10.1006/geno.1994.1348. PMID7959795.
Maruyama K, Sugano S (Jan 1994). "Oligo-capping: a simple method to replace the cap structure of eukaryotic mRNAs with oligoribonucleotides". Gene. 138 (1-2): 171–4. doi:10.1016/0378-1119(94)90802-8. PMID8125298.
Jacobsen L, Madsen P, Moestrup SK, Lund AH, Tommerup N, Nykjaer A, Sottrup-Jensen L, Gliemann J, Petersen CM (Dec 1996). "Molecular characterization of a novel human hybrid-type receptor that binds the alpha2-macroglobulin receptor-associated protein". The Journal of Biological Chemistry. 271 (49): 31379–83. doi:10.1074/jbc.271.49.31379. PMID8940146.
Bu G, Rennke S, Geuze HJ (Jan 1997). "ERD2 proteins mediate ER retention of the HNEL signal of LRP's receptor-associated protein (RAP)". Journal of Cell Science. 110. 110 ( Pt 1): 65–73. PMID9010785.
Petersen CM, Nielsen MS, Nykjaer A, Jacobsen L, Tommerup N, Rasmussen HH, Roigaard H, Gliemann J, Madsen P, Moestrup SK (Feb 1997). "Molecular identification of a novel candidate sorting receptor purified from human brain by receptor-associated protein affinity chromatography". The Journal of Biological Chemistry. 272 (6): 3599–605. doi:10.1074/jbc.272.6.3599. PMID9013611.